If PEAK (bezuclastinib + sunitinib) is approved, how would it influence your second-line treatment strategy for patients with advanced KIT-mutant GIST following imatinib failure?
Wagner et al., ASCO 2026
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Miami Sylvester Comprehensive Cancer Center
Answered on
This will be the preferred second-line therapy.
Join for free or sign in to see the full answer